OncLive TV

Jane Armer on Cancers That Frequently Develop Lymphedema

Susan Moore on Predictors of Poor Oral Oncolytic Adherence

Julia Whiteker Describes the ONS Breast Care SIG Online Community

Susan Moore Describes Advantages of Oral Oncolytics

Julia Whiteker Discusses the Value of Social Media to Oncology Nurses

Julia Whiteker from the Oncology Nursing Society Breast Care SIG on Maintaining a Social Media Community

Julia Whiteker on the Oncology Nursing Society Breast Care Special Interest Groups's Future Goals

Carol Tringali on Closing the Gaps in Psychosocial Care

Julia Whiteker on Social Media Guidelines for Online Communities

Carol Tringali from Penn State Hershey Medical Center Explains the Gaps in Psychosocial Care

Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study

Jamie Myers Explains Results From Her Chemotherapy-Related Cognitive Impairment Study

Fiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion

Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments

Carol Tringali from Penn State Hershey Medical Center Discusses the Schwartz Center Rounds Program

David Cornfield Melanoma Fund Presents Dear 16-Year-Old Me

Dr. Patrick Cobb from the Community Oncology Alliance on the Complications of Reimbursement in Oncology

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Ted Okon Explains Why he Foresees a Shortage of Oncologists in the Future

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Ted Okon Talks About the Issues With Reimbursement

Dr. Cobb Discusses the Implications of the Value Based Insurance Design

Dr. Crawford Discusses Alternatives to Biopsy in Prostate Cancer

Ted Okon Discusses the Ramifications of Hospitals Acquiring Community Clinics

Dr. Cobb Talks About a Possible Oncologist Shortage in a Few Years

Dr. David Pearlstone from John Theurer Cancer Center Discusses Mammogram Deterrents

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial